[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100300501":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":7,"locations":8,"responsibleParty":21,"collaborators":7,"id":23,"slug":24,"hasResults":25,"nctId":26,"briefTitle":27,"officialTitle":28,"acronym":7,"eligibilityCriteria":29,"healthyVolunteers":30,"sex":31,"minAge":32,"maxAge":33,"enrollmentInfo":34,"targetDuration":37,"studyType":38,"phases":7,"briefSummary":39,"conditions":40,"keywords":43,"overallStatus":45,"whyStopped":46,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":55},{"fullName":5,"class":6},"Anecova SA","INDUSTRY",null,[9],{"facility":10,"status":7,"city":11,"state":12,"zip":7,"country":13,"countryCode":14,"cosmosGeoPoint":15,"geoPoint":20,"contacts":7},"IVI Bilbao","Leioa","Basque Country","Spain","ES",{"type":16,"coordinates":17},"Point",[18,19],-2.98884,43.32686,{"lat":19,"lon":18},{"type":22,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100300501","post-market-surveillance--post-market-clinical-follow-up-international-medical-registry-to-confirm-the-safety-and-the-performance-of-the-anecova-intra-uterine-culture-device-100300501",false,"NCT03191890","Post Market Surveillance & Post Market Clinical Follow up, International, Medical Registry to Confirm the Safety and the Performance of the Anecova Intra Uterine Culture Device","Observational, Non-Interventional, Prospective, Post Market Surveillance & Post Market Clinical Follow up, International, Medical Registry to Confirm the Safety and the Performance of the Anecova Intra Uterine Culture Device for Participants With Subfertility Issue Undergoing Assisted Reproductive Medical Treatment in Routine Clinical Practice","Inclusion Criteria:\n\n* Age between 18 and 43,\n* Hormonal serum levels within normal ranges for the routinely or specifically tested hormones (FSH, LH, AMH, E2, PRL, P4, TSH),\n* BMI between 18 and 29, If assessed normal antral follicular count and regular menses\n\nExclusion Criteria:\n\n* Endometrial, autoimmune or hormonal specificities, as well as presence of pathology that could be potentially deleterious to the healthy development of embryos in the uterine cavity (i.e. severe endometriosis),\n* Acute or chronic gynecological infection",true,"FEMALE","18 Years","43 Years",{"count":35,"type":36},0,"ACTUAL","9 Weeks","OBSERVATIONAL","This study is designed to generate a comprehensive survey of the use on the market of the Anecova device within its intended indications according to the Instructions For Use. The Anecova Registry is part of the Anecova quality system, to enable the Post Marketing Surveillance and the Post Market Clinical Follow-up.",[41,42],"Infertility","Reproductive Sterility",[44],"in vivo culture","WITHDRAWN","Sponsor stopped the study due to poor enrollment","2019-04-03",{"date":49,"type":36},"2019-04-04",{"date":51,"type":36},"2017-06-15",{"date":53,"type":36},"2018-03-31",{"name":5,"class":6},1]